Source: FirstWord Pharma

Active Biotech: Active Biotech strengthens the patent protection for laquinimod in eye disorders

Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has issued a decision to grant Active Biotech's patent related to use of laquini...

Read full article »
Annual Revenue
$ < 1M
Employees
17
Tomas Leanderson's photo - President & CEO of Active Biotech

President & CEO

Tomas Leanderson

CEO Approval Rating

69/100

Read more